PTC
ANIK icon

Petrus Trust Company’s Anika Therapeutics ANIK Stock Holding History

Petrus Trust Company’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-5,955
Closed -$200K – 265
2018
Q4 		$200K Buy
+5,955
New +$215K 0.04% 189

Other funds holding ANIK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
BTW
Boston Trust Walden Boston, Massachusetts $12.2B AUM 12.45% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Petrus Trust Company's ANIK Position: Q1 2019 in Review

Petrus Trust Company sold out of Anika Therapeutics (ANIK) in Q1 2019, closing a stake of 5,955 shares — an estimated $200K sold.

Petrus Trust Company first reported a position in ANIK in Q4 2018 and held it in 1 quarter. The position peaked at $200K in Q4 2018. 157 funds tracked by Wall St. Rank hold ANIK as of Q1 2019.

  • Petrus Trust Company reported no remaining Anika Therapeutics position as of Q1 2019 after selling out during the quarter.
  • Petrus Trust Company sold 5,955 Anika Therapeutics shares in Q1 2019, an estimated $200K.
  • Petrus Trust Company first reported a position in Anika Therapeutics in Q4 2018 and held it in 1 quarter.
  • Petrus Trust Company's Anika Therapeutics position peaked at $200K in Q4 2018.
  • 157 funds tracked by Wall St. Rank held Anika Therapeutics as of Q1 2019.

Based on Petrus Trust Company's 13F filing for Q1 2019, filed 15 May 2019.